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measurement experts to generate items, responses, and instructions for the new scale. 
Cognitive interviews were conducted with an additional 15 idiopathic RLS patients 
(aged 25–68) to ensure understanding of the new measure, concept comprehensive-
ness, and to identify any necessary revisions to the items and conceptual framework. 
RESULTS: Twenty-three items were generated from patient quotes obtained during 
the concept elicitation interviews. Impacts on next day functioning spontaneously 
attributed to disturbed sleep due to RLS symptoms included: activities of daily living 
(i.e., work, household chores), cognitive functioning (i.e., concentration, forgetfulness, 
mental tiredness, alertness), emotional functioning (i.e., irritability, depressed mood), 
physical functioning (i.e., physical tiredness, active leisure activities), energy, daytime 
sleepiness, and social functioning (i.e., relationships, social activities/situations). 
Concept saturation was achieved. Modiﬁcations to questions and responses were 
based on feedback provided during cognitive interviews. The ﬁnal measure consists 
of 14 items assessed “today” and rated on a severity numeric rating scale. CONCLU-
SIONS: The RLS-NDI is an evaluative tool with demonstrated content validity to 
assess the impact of disturbed sleep due to RLS symptoms on RLS patients’ next day 
functioning.
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OBJECTIVES: Parkinson’s disease (PD) is the second most prevalent neurodegenera-
tive disorder in the US. The Scales for Outcomes in Patients with Parkinson’s disease 
Diary Card (SCOPA-DC) is a daily diary designed to measure motor impairment in 
PD patients with ﬂuctuating symptoms. Consistent with the FDA’s ﬁnal guidance on 
patient-reported outcome measures, this study aimed to evaluate the content validity 
of the SCOPA-DC in the US and determine the feasibility of adding items that measure 
non-motor symptoms using qualitative techniques. METHODS: A literature review 
identiﬁed the most dominant non-motor symptoms experienced by PD patients with 
ﬂuctuating symptoms. Three focus groups were conducted with PD patients (n = 24) 
to identify themes that speciﬁcally addressed the study objectives. The original 
SCOPA-DC was modiﬁed based on ﬁndings from the literature review and patient 
input. A fourth focus group (n = 9) consisted of a cognitive debrieﬁng of the revised 
SCOPA-DC that included additional items and modiﬁed structure based upon the 
previous results. RESULTS: Findings from the focus groups demonstrated support for 
the content of the original SCOPA-DC, generally ﬁnding it to be clear and intuitive, 
despite difﬁculties with some item deﬁnitions, time frames, and response labels. With 
respect to non-motor symptoms, seven domains were consistently mentioned: fatigue, 
concentration/memory, anxiety, pain, difﬁculty swallowing, frequent urination, and 
sweating. The cognitive debrieﬁng focus group reported that the revised SCOPA-DC 
format was easier to use, provided better focus on the items and time frames, and 
more adequately captured experiences throughout the day as compared to the original. 
CONCLUSIONS: Non-motor symptoms occur frequently in PD patients with ﬂuctu-
ating symptoms and have a signiﬁcant impact on health-related quality of life. A 
reliable and validated patient-reported daily diary may improve the ability to describe 
PD progression by accurately measuring both motor and non-motor symptoms. Addi-
tional quantitative research is needed to evaluate the psychometric properties of the 
revised SCOPA-DC.
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OBJECTIVES: To provide evidence for the reliability and validity of the Migraine-
Speciﬁc Quality of Life Questionnaire Version 2.1 (MSQ) for use across migraine 
disorders. METHODS: Cross-sectional data were collected via web-based survey in 
nine countries/regions. Participants were classiﬁed per ICHD-2 criteria as having 
chronic migraine (CM, ≥15 headache days/month), high-frequency episodic migraine 
(HEM, 10–14 headache days/month), or low-frequency episodic migraine (LEM, ≤9 
headache days/month). Three MSQ domains Role Function-Preventive (RP), Role 
Function-Restrictive (RR), and Emotional Function (EF) were rescaled to 0–100, 
where higher scores indicate better health-related quality of life (HRQOL), and ana-
lyzed for internal consistency reliability (Cronbach’s alpha), construct validity (cor-
relations assessed between MSQ scales and measures of depression/anxiety [Patient 
Health Questionnaire; PHQ-4], disability [Migraine Disability Assessment Question-
naire; MIDAS], and functional impact [Headache Impact Test; HIT-6], where lower 
scores indicate better HRQOL for each), as well as discriminant validity across 
migraine groups. RESULTS: A total of 8726 eligible respondents were classiﬁed as 
follows: 5.7% CM (n = 499), 5.9% HEM (n = 515), and 88.4% LEM (n = 7,712). 
Migraineurs were mostly female (83.5%) with a mean (±SD) age of 40.3 ± 11.4, 
similar across the groups. MSQ domain scores for CM, HEM, and LEM groups 
respectively were: RP = 61.4 ± 26.1, 65.9 ± 23.8, and 72.1 ± 23.9; RR = 44.4 ± 22.1, 
48.3 ± 22.8, and 57.0 ± 24.1; EF = 48.3 ± 28.1, 57.8 ± 27.7, and 67.8 ± 26.5. Internal 
consistency of the total sample for RP, RR, and EF was 0.90, 0.96, and 0.87, respec-
tively. Similar values were observed across migraine groups. Varied by domains and 
migraine groups, MSQ scores correlated moderately to highly with scores from the 
PHQ-4 (r = −0.28 to −0.47), MIDAS (r = −0.42 to −0.58), and HIT-6 (r = −0.55 to 
−0.71). Known groups validity indicated signiﬁcant differences (p < 0.0001) in the 
hypothesized direction between CM, HEM, and LEM for RP (F = 58.74), RR (F = 
91.78), and EF (F = 153.38). CONCLUSIONS: The MSQ is a reliable and valid 
questionnaire that can differentiate the functional impact between CM, HEM, and 
LEM.
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OBJECTIVES: The Migraine-Speciﬁc Quality of Life Questionnaire Version 2.1 
(MSQ) is a 14-item health-related quality of life instrument that measures the func-
tional impact of migraine across three domains: Role Function-Preventive (RP), Role 
Function-Restrictive (RR), and Emotional Function (EF). This study evaluated the 
factor structure and cross-cultural comparability of the MSQ in Chronic Migraine 
(CM) sufferers. METHODS: Cross-sectional data were collected via web-based 
survey, across eight countries. Respondents were classiﬁed as having CM per ICHD-2 
criteria with ≥15 headache days/month (n = 499). Conﬁrmatory factor analysis (CFA) 
of the 3-factor model was conducted using the robust maximum likelihood estimator 
(MLR) assuming multivariate normality. Goodness-of-ﬁt was assessed by the com-
parative ﬁt index (CFI), Tucker-Lewis Index (TFI), and root mean square error of 
approximation (RSMEA). Differential item functioning (DIF) was tested using ordinal 
logistic regression of MSQ item scores on group membership and trait level explana-
tory variables. Groups were based on country (Australia, Canada, Germany, Spain, 
France, Great Britain, Italy, United States) and language (English/non-English). Non-
uniform DIF (signiﬁcant interaction term between group membership and trait level, 
p < 0.05) and uniform DIF (>10% change in the trait level coefﬁcient resulting from 
removal of the group membership term from the model) were identiﬁed. RESULTS: 
The 3-factor model demonstrated good ﬁt (CFI = 0.97; TFI = 0.96; RMSEA = 0.07) 
among CM sufferers. Factor loadings ranged between 0.72 and 0.89, and had similar 
values across the three factors. Most MSQ items showed absence of DIF. Non-uniform 
country DIF was identiﬁed in items 5 (inability to concentrate; p = 0.028) and 12 (fed 
up or frustrated; p = 0.037). Item 12 also presented non-uniform DIF related to 
language (p = 0.010). CONCLUSIONS: Among Chronic Migraineurs, the MSQ 
provides a valid measure of RP, RR, and EF, yielding domain scores that can be reli-
ably compared across languages and countries.
PND28
CROSS CULTURAL EVALUATION OF THE SHORT FORM 8 ITEM 
PARKINSON’S DISEASE QUESTIONNAIRE: RESULTS FROM AMERICA, 
CANADA, JAPAN, ITALY AND SPAIN
Jenkinson C1, Fitzpatrick R1, Findley L2, Churchman D3, Hughes K4
1University of Oxford, Health Services Research Unit, Oxford, Oxfordshire, UK, 2Oldchurch 
Hospital, Romford, Essex, UK, 3Isis Innovation Ltd, Oxford, UK, 4The Planning Shop 
International, London, London, UK
OBJECTIVES: Increasingly health status measures, used to measure the subjective 
functioning and well being of respondents, are being used in trials of treatments which 
are undertaken in a variety of countries. The purpose of this study was to evaluate 
the psychometric properties of a short form health survey, the Parkinson’s Disease 
Questionnaire (PDQ-8), cross-culturally, by comparing results gained from this instru-
ment to the original longer form instrument—the PDQ-39. METHODS: Data are 
from the Global Parkinson’s Disease Survey (GPDS) a cross national survey which 
utilised the thirty nine item Parkinson’s Disease Questionnaire (PDQ-39) as a major 
outcome measure. In this study, we evaluate results from the PDQ-8 (Single Index 
Score PDQ-8-SI) with results from the parent form (from which the PDQ-8 was 
derived), of the instrument in the USA, Canada, Spain, Italy and Japan. RESULTS: 
We evaluate response rate (97% of the 819 respondents completed all items on 
PDQ-8), data quality, score reliability (internal reliability of the eight items of the 
PDQ-8 was calculated for all countries using Cronbach’s alpha, USA = 0.88; Canada 
= 0.83; Italy = 0.87; Spain = 0.79 and Japan = 0.73) and scaling assumptions of the 
instrument in the USA, Canada, Spain, Italy and Japan. CONCLUSIONS: The evi-
dence suggests that PDQ-8-SI seems a useful measure in studies where a short measure, 
providing an overall index of self perceived health in PD, is required. The PDQ-8 is 
a practical and informative instrument for the evaluation of overall quality of life of 
PD patients in cross-cultural studies.
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OBJECTIVES: Bladder dysfunction is a common symptom in patients with multiple 
sclerosis (MS). This study assessed the current literature regarding instruments that 
have been used to measure the health-related quality of life (HRQOL) impact of this 
chronic illness, and to what extent bladder dysfunction affects HRQOL in this popula-
tion. METHODS: Two searches using MEDLINE/PubMed’s MeSH database were 
made. Quality of life was isolated by checking the psychology subheading within the 
